Literature DB >> 8343706

Management of raised blood pressure in New Zealand: a discussion document.

R Jackson1, P Barham, J Bills, T Birch, L McLennan, S MacMahon, T Maling.   

Abstract

A report to the National Advisory Committee on Core Health and Disability Support Services, New Zealand, on the management of raised blood pressure recommends that decisions to treat raised blood pressure should be based primarily on the estimated absolute risk of cardiovascular disease rather than on blood pressure alone. In general, patients with a blood pressure of 150-170 mm Hg systolic or 90-100 mm Hg diastolic, or both, should be given treatment to lower blood pressure if the risk of a major cardiovascular disease event in 10 years is more than about 20%. The results of clinical trials indicate that, at this level of absolute risk, 150 people would require treatment to reduce the annual number of cardiovascular events by about one. Implementation of these recommendations may result in a smaller proportion of people aged under 60, particularly women, receiving treatment but an increased proportion of older people treated. In the absence of specific contraindications, low dose diuretics and low dose beta blockers should be considered for first line treatment, since for only these drug groups is there direct evidence of reduced risk of stroke and coronary disease in people with raised blood pressure.

Entities:  

Mesh:

Year:  1993        PMID: 8343706      PMCID: PMC1693500          DOI: 10.1136/bmj.307.6896.107

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  7 in total

Review 1.  The evolution of antihypertensive therapy.

Authors:  I Kawachi; N Wilson
Journal:  Soc Sci Med       Date:  1990       Impact factor: 4.634

2.  An updated coronary risk profile. A statement for health professionals.

Authors:  K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

3.  Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.

Authors:  J E Carlsen; L Køber; C Torp-Pedersen; P Johansen
Journal:  BMJ       Date:  1990-04-14

4.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

5.  Benefits and potential harm of lowering high blood pressure.

Authors:  J M Cruickshank; J M Thorp; F J Zacharias
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

Review 6.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

7.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Authors:  S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

  7 in total
  62 in total

Review 1.  What is the optimal age for starting lipid lowering treatment? A mathematical model.

Authors:  S Ulrich; A D Hingorani; J Martin; P Vallance
Journal:  BMJ       Date:  2000-04-22

2.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

3.  Management of UTI in general practice: a cost effective analysis. A commentary to facilitate an understanding of economic evaluation.

Authors:  D Kernick
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

4.  Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.

Authors:  L D Ritchie
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

5.  The primary prevention of coronary heart disease with statins: practice headache or public health?

Authors:  P H Evans
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

6.  Models to predict cardiovascular risk: comparison of CART, multilayer perceptron and logistic regression.

Authors:  I Colombet; A Ruelland; G Chatellier; F Gueyffier; P Degoulet; M C Jaulent
Journal:  Proc AMIA Symp       Date:  2000

7.  Prediction of cardiovascular risk. Program is not suitable for diabetic patients.

Authors:  A Zambanini; M R Smith; M D Feher
Journal:  BMJ       Date:  1999-05-22

Review 8.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

9.  Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.

Authors:  I U Haq; L E Ramsay; W W Yeo; P R Jackson; E J Wallis
Journal:  Heart       Date:  1999-01       Impact factor: 5.994

10.  Risk factor scoring for coronary heart disease.

Authors:  Hans-Werner Hense
Journal:  BMJ       Date:  2003-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.